MRKR — Marker Therapeutics Share Price
0.000.00%
Last trade - 00:00- $38.37m
- $23.26m
- $3.31m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.73 | ||
| Price to Tang. Book | 2.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.59 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -103.76% | ||
| Return on Equity | -83.47% | ||
| Operating Margin | -440.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.21 | 0.47 | 1.24 | 3.51 | 3.31 | n/a | n/a | 74.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Directors
- Frederick Wasserman NEC (67)
- Peter Hoang PRE (49)
- Anthony Kim CFO (45)
- Juan Vera COO (41)
- Michael Loiacono CAO (55)
- Nadia Agopyan VPR (59)
- Gerald Garrett VPR (56)
- Tsvetelina Hoang VPR (48)
- Anna Szymanska VPR (47)
- Mythili Koneru OTH (43)
- Katharine Knobil DRC (57)
- N. David Eansor IND (60)
- Steven Elms IND (57)
- David Laskow-Pooley IND (66)
- John Wilson IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 17th, 2018
- Public Since
- November 8th, 2016
- No. of Shareholders
- 36
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 8,902,897
- Address
- 4551 KENNEDY COMMERCE DR., HOUSTON, 77032
- Web
- https://markertherapeutics.com/
- Phone
- +1 7134006400
- Auditors
- Marcum LLP
Upcoming Events for MRKR
Marker Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Marker Therapeutics Inc Earnings Release
Similar to MRKR
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Marker Therapeutics share price?
As of Today at 19:13 UTC, shares in Marker Therapeutics are trading at $4.31. This share price information is delayed by 15 minutes.
How has the Marker Therapeutics share price performed this year?
Shares in Marker Therapeutics last closed at $4.31 and the price had moved by +358.51% over the past 365 days. In terms of relative price strength the Marker Therapeutics share price has outperformed the S&P500 Index by +270.29% over the past year.
What are the analyst and broker recommendations for Marker Therapeutics?
The overall consensus recommendation for Marker Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Marker Therapeutics dividend yield?
Marker Therapeutics does not currently pay a dividend.
Does Marker Therapeutics pay a dividend?
Marker Therapeutics does not currently pay a dividend.
When does Marker Therapeutics next pay dividends?
Marker Therapeutics does not currently pay a dividend.
How do I buy Marker Therapeutics shares?
To buy shares in Marker Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Marker Therapeutics?
As of the previous close price of $4.31, shares in Marker Therapeutics had a market capitalisation of $38.37m.
Where are Marker Therapeutics shares listed?
Here are the trading details for Marker Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MRKR
What kind of share is Marker Therapeutics?
Based on an overall assessment of its quality, value and momentum Marker Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Marker Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Marker Therapeutics is $12.50. That is 190.02% above the last closing price of $4.31.
Analysts covering Marker Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the Marker Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Marker Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +11.16%.
As of the last closing price of $4.31, shares in Marker Therapeutics were trading -2.91% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Marker Therapeutics PE Ratio?
The Marker Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Marker Therapeutics?
Marker Therapeutics' management team is headed by:
- Frederick Wasserman - NEC
- Peter Hoang - PRE
- Anthony Kim - CFO
- Juan Vera - COO
- Michael Loiacono - CAO
- Nadia Agopyan - VPR
- Gerald Garrett - VPR
- Tsvetelina Hoang - VPR
- Anna Szymanska - VPR
- Mythili Koneru - OTH
- Katharine Knobil - DRC
- N. David Eansor - IND
- Steven Elms - IND
- David Laskow-Pooley - IND
- John Wilson - IND